DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: TYSABRI (natalizumab)
*****************************************************
#Post#: 2011--------------------------------------------------
Relationship between Tysabri-related PML and the JC virus
By: agate Date: March 13, 2018, 1:38 am
---------------------------------------------------------
JAMA Neurology (March 12) contains two articles investigating
the relationship between Tysabri-related PML and the JC virus:
"Association of progressive multifocal leukoencephalopathy
lesion volume with JC virus polymerase chain reaction results in
cerebrospinal fluid of natalizumab-treated patients with
multiple sclerosis":
HTML https://jamanetwork.com/journals/jamaneurology/article-abstract/2674280?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaneurology&utm_content=olf&utm_term=031218&redirect=true
"Progressive multifocal leucoencephalopathy lesions and JC
virus: The limits and value of imaging":
HTML https://jamanetwork.com/journals/jamaneurology/fullarticle/2674273?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaneurology&utm_content=olf&utm_term=031218
#Post#: 2328--------------------------------------------------
Article on connection between PML and JC virus one of most talke
d about articles of 2018
By: agate Date: December 30, 2018, 7:59 pm
---------------------------------------------------------
The article cited in the previous post has been chosen as one of
the 10 most talked about articles in JAMA Neurology in 2018. The
link below gives the entire article:
HTML https://jamanetwork.com/journals/jamaneurology/fullarticle/2674280?guestAccessKey=bab12c9a-021f-493d-bddc-27f5a7166a79&utm_source=silverchair&utm_campaign=altmetric&utm_content=2018_year-end&cmp=1&utm_medium=email
*****************************************************